3.0 T neuroimaging: technical considerations and clinical applications.
Since approval by the US Food and Drug Administration (FDA) in 2000, human MR imaging at field strength up to 4.0 T in clinical practice and up to 8.0 T on research systems has become available. Although human MR imaging at field strengths greater than 1.5 T was performed even before 1999 on research systems, the FDA approval for clinical use and the advent of actively shielded magnets marked a new trend for MR vendors and users. Because of the potential technical benefits when moving from 1.5 T to 3.0 T, the number of 3.0 T installations is increasing continuously worldwide. This article reviews the benefits, challenges, and the current knowledge of 3.0 T whole body MR imaging and summarizes its clinical applications.
Willinek
Winfried A
WA
Department of Radiology, University of Bonn, Sigmund-Freud-Strasse 25, D-53105 Bonn, Germany. winfried.willinek@ukb.uni-bonn.de
Kuhl
Christiane K
CK
D000328:Adult; D001921:Brain / Q000473:pathology*; D003287:Contrast Media; D038524:Diffusion Magnetic Resonance Imaging / Q000379:methods; D005260:Female; D006801:Humans; D018810:Magnetic Resonance Angiography / Q000379:methods; D008279:Magnetic Resonance Imaging / Q000379:methods; D009682:Magnetic Resonance Spectroscopy / Q000379:methods; D008280:Magnetics; D008297:Male; D008875:Middle Aged; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D013113:Spin Labels; D013997:Time Factors
D003287:Contrast Media; D013113:Spin Labels